10:24 AM EDT, 10/22/2024 (MT Newswires) -- SIGA Technologies ( SIGA ) said Tuesday it entered into a license agreement with Vanderbilt University for a portfolio of preclinical fully human monoclonal antibodies with potential treatments for various orthopoxviruses, including smallpox and mpox.

Financial terms weren't disclosed.

Under the agreement, SIGA ( SIGA ) said it has exercised its option to license the exclusive rights to develop, manufacture, and commercialize the mAbs globally.

Shares of SIGA ( SIGA ) were down over 2% in recent trading.

Price: 6.71, Change: -0.18, Percent Change: -2.54